Efficacy and Safety of SBRT Combined With Becotatug Vedotin in EGFR-Positive Metastatic Tumor Patients With Oligometastases

The combination of local consolidative treatment for oligometastases and systemic therapy offers the potential for clinical cure and significantly prolongs survival in a subset of patients with advanced metastatic disease. However, a considerable number of patients still do not benefit from this approach. Becotatug vedotin is an antibody-drug conjugate that carries the payload Monomethyl auristatin E (MMAE), a microtubule inhibitor. In various preclinical tumor models, including head and neck squamous cell carcinoma, liver cancer, gastric cancer, pancreatic cancer, and lung cancer, MMAE has been shown to effectively enhance radiosensitivity. Furthermore, multiple clinical studies have demonstrated the promising therapeutic potential of vicetuximab in EGFR-positive solid tumors. Based on this background, we plan to conduct a clinical study evaluating stereotactic body radiotherapy (SBRT) for oligometastases combined with investigator-selected systemic therapy, in conjunction with Becotatug vedotin, for the treatment of patients with EGFR-positive oligometastatic tumors.